Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
40 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Arrhythmias - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Arrhythmias - Pipeline Review, H2 2014', provides an overview of the Arrhythmias's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Arrhythmias, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arrhythmias and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Arrhythmias - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Arrhythmias and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Arrhythmias products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Arrhythmias pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Arrhythmias - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Arrhythmias pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Arrhythmias Overview 6 Therapeutics Development 7 Pipeline Products for Arrhythmias - Overview 7 Pipeline Products for Arrhythmias - Comparative Analysis 8 Arrhythmias - Therapeutics under Development by Companies 9 Arrhythmias - Therapeutics under Investigation by Universities/Institutes 10 Arrhythmias - Pipeline Products Glance 11 Early Stage Products 11 Arrhythmias - Products under Development by Companies 12 Arrhythmias - Products under Investigation by Universities/Institutes 13 Arrhythmias - Companies Involved in Therapeutics Development 14 Gilead Sciences, Inc. 14 Orion Oyj 15 SciFluor Life Sciences, LLC 16 Nyken BV 17 Arrhythmias - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Target 19 Assessment by Mechanism of Action 21 Assessment by Molecule Type 23 Drug Profiles 25 F-15845 - Drug Profile 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 NYK-1112 - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 GS-967 - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Small Molecules For Arrhythmia - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Small Molecules to Antagonize Ryanodine Receptor for Cardiac Arrhythmias - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 ORM-10103 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 KN-93 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 PP-1 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Small Molecules to Inhibit Vesicular Acetylcholine Transporter for Arrhythmias - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Arrhythmias - Dormant Projects 36 Arrhythmias - Discontinued Products 37 Arrhythmias - Product Development Milestones 38 Featured News & Press Releases 38 Mar 01, 2011: Geron Announces Preclinical Study Data Of GRNCM1 38 Appendix 39 Methodology 39 Coverage 39 Secondary Research 39 Primary Research 39 Expert Panel Validation 39 Contact Us 40 Disclaimer 40
List of Tables Number of Products under Development for Arrhythmias, H2 2014 7 Number of Products under Development for Arrhythmias - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Number of Products under Investigation by Universities/Institutes, H2 2014 10 Comparative Analysis by Early Stage Development, H2 2014 11 Products under Development by Companies, H2 2014 12 Products under Investigation by Universities/Institutes, H2 2014 13 Arrhythmias - Pipeline by Gilead Sciences, Inc., H2 2014 14 Arrhythmias - Pipeline by Orion Oyj, H2 2014 15 Arrhythmias - Pipeline by SciFluor Life Sciences, LLC, H2 2014 16 Arrhythmias - Pipeline by Nyken BV, H2 2014 17 Assessment by Monotherapy Products, H2 2014 18 Number of Products by Stage and Target, H2 2014 20 Number of Products by Stage and Mechanism of Action, H2 2014 22 Number of Products by Stage and Molecule Type, H2 2014 24 Arrhythmias - Dormant Projects, H2 2014 36 Arrhythmias - Discontinued Products, H2 2014 37
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.